Patents by Inventor Gunnar F. Kaufmann

Gunnar F. Kaufmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220363758
    Abstract: The present disclosure provides heterodimeric antibodies that bind to two different target antigens at the same time. In one embodiment, the heterodimeric antibodies are bispecific antibodies. In one embodiment, the heterodimeric antibodies comprise three polypeptides including: a first polypeptide comprising an scFv-Fc fusion polypeptide; a second polypeptide comprising an immunoglobulin heavy chain; and a third polypeptide comprising an immunoglobulin light chain. In one embodiment, the first polypeptide includes one or more point mutations that confer increased thermal-stability to the first polypeptide.
    Type: Application
    Filed: June 30, 2020
    Publication date: November 17, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Xiao He, Yanliang Zhang, Yun Wei Lai, Gunnar F. Kaufmann, Barbara A. Swanson, Lisa Diane Kerwin, Susan M. Richards
  • Publication number: 20220324974
    Abstract: The present disclosure provides several embodiments of multi-specific antigen binding protein complexes. In some embodiments, the multi-specific antigen binding protein complex is composed of either two or three polypeptide chains that assemble with each other to form het-erodimeric complexes comprising two different Fab regions each capable of binding two different epitopes and comprising an Fc region which is capable of exhibiting Fc effector function, thus having a relatively simple structure compared to certain other multi-specific antibodies. In one embodiment, the multi-specific antigen binding protein complex is activatable as one of the polypeptide chains that compose the protein complex carries a cleavable linker.
    Type: Application
    Filed: April 10, 2020
    Publication date: October 13, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Yanliang Zhang, Gunnar F. Kaufmann, Xiao He, Yun Wei Lai
  • Publication number: 20220251168
    Abstract: The present disclosure provides dimeric antigen receptors (DAR) constructs that bind a BCMA target antigen, where the DAR construct comprises a heavy chain binding region on one polypeptide chain and a light chain binding region on a separate polypeptide chain. The two polypeptide chains that make up the dimeric antigen receptors can dimerize to form an antigen binding domain. The dimeric antigen receptors have antibody-like properties as they bind specifically to a target antigen. The dimeric antigen receptors can be used for directed cell therapy.
    Type: Application
    Filed: March 3, 2022
    Publication date: August 11, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Henry Hongjun Ji, Wenzhong Guo, Yanliang Zhang, Bei Bei Ding, Gunnar F. Kaufmann
  • Publication number: 20220242954
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Application
    Filed: December 17, 2021
    Publication date: August 4, 2022
    Inventors: Heyue Zhou, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann, Edwige Gros
  • Publication number: 20220144971
    Abstract: Provided are bispecific antibody compounds having the Formula I: wherein, FAB1, FAB2, and —X— are as defined herein. The provided bispecific antibody compounds can be used a modulators of target molecules, including CD3, PSMA, CD19, CXCR5, CD33, PDL1, VEGFR2, cMet, or Axl, and are useful in the treatment of one or more conditions.
    Type: Application
    Filed: January 26, 2022
    Publication date: May 12, 2022
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar F. Kaufmann, James T. Patterson
  • Patent number: 11318202
    Abstract: There is disclosed compositions and methods relating to or derived from anti-WISP1 antibodies. More specifically, there is disclosed fully human antibodies that bind WISP1, WISP1-binding fragments and derivatives of such antibodies, and WISP1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having WISP1 related disorders or conditions. There is also disclosed a method for treating or preventing various cancers or inflammatory diseases and various diseases of the heart, bone/joints or lung.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: May 3, 2022
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Gunnar F. Kaufmann
  • Patent number: 11267905
    Abstract: Provided are bispecific antibody compounds having the Formula I: wherein, FAB1, FAB2, and —X— are as defined herein. The provided bispecific antibody compounds can be used a modulators of target molecules, including CD3, PSMA, CD19, CXCR5, CD33, PDL1, VEGFR2, cMet, or Ax1, and are useful in the treatment of one or more conditions.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: March 8, 2022
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar F. Kaufmann, James T. Patterson
  • Patent number: 11242391
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: February 8, 2022
    Assignee: SORRENTO THERAPEUTICS, INC.
    Inventors: Heyue Zhou, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann, Edwige Gros
  • Publication number: 20210330787
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Application
    Filed: May 3, 2021
    Publication date: October 28, 2021
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
  • Patent number: 11027012
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: June 8, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
  • Publication number: 20210138075
    Abstract: Provided herein are cell penetrating compounds having the Formula I: where, generally, each T is a thiol reactive group (e.g., a phosphorothioate), each L is a linker (e.g., a linear alkyl), and Y is a biologic (e.g., an antibody). Also provided are pharmaceutical compositions including the cell penetrating compounds, and methods of delivering the compound into a cell.
    Type: Application
    Filed: January 20, 2021
    Publication date: May 13, 2021
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar F. Kaufmann, Heehyoung Lee, Tong Zhu, Henry Hongjun Ji
  • Publication number: 20210130468
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Application
    Filed: January 14, 2020
    Publication date: May 6, 2021
    Inventors: Heyue Zhou, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann, Edwige Gros
  • Publication number: 20210052738
    Abstract: Provided are bispecific conjugates having the general formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancer.
    Type: Application
    Filed: August 31, 2020
    Publication date: February 25, 2021
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: James T. Patterson, Gunnar F. Kaufmann, Yanwen Fu, Tong Zhu
  • Patent number: 10925968
    Abstract: Provided herein are cell penetrating compounds having the Formula I: where, generally, each T is a thiol reactive group (e.g., a phosphorothioate), each L is a linker (e.g., a linear alkyl), and Y is a biologic (e.g., an antibody). Also provided are pharmaceutical compositions including the cell penetrating compounds, and methods of delivering the compound into a cell.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: February 23, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar F. Kaufmann, Heehyoung Lee, Tong Zhu, Henry Hongjun Ji
  • Publication number: 20200399393
    Abstract: The present disclosure provides dimeric antigen receptors (DAR) constructs comprising a heavy chain binding region on one polypeptide chain and a light chain binding region on a separate polypeptide chain. The two polypeptide chains that make up the dimeric antigen receptors can dimerize to form an antigen binding domain. The dimeric antigen receptors have antibody-like properties as they bind specifically to a target antigen. The dimeric antigen receptors can be used for directed cell therapy.
    Type: Application
    Filed: September 4, 2020
    Publication date: December 24, 2020
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Henry Hongjun Ji, Wenzhong Guo, Yanliang Zhang, Gunnar F. Kaufmann, Bei Bei Ding
  • Patent number: 10799598
    Abstract: Provided are bispecific conjugates having the general formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancer.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: October 13, 2020
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: James T. Patterson, Gunnar F. Kaufmann, Yanwen Fu, Tong Zhu
  • Patent number: 10774135
    Abstract: The present disclosure provides fully human variant anti-AIP2 variant antibodies, and antigen binding proteins thereof, having improved characteristics compared to the wild type anti-AIP2 antibody E7 from which the variant clones are derived. The variant anti-AIP2 antibodies exhibit improved binding to AIP1 and AIP4 as determined in an in vitro quorum sensing reporter assay, have improved thermal stability, provided complete protection against infection with two different strains of Staphylococcus aureus MRSA in pre-treated mice, and can be manufactured at higher yields.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: September 15, 2020
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Yanliang Zhang, Gunnar F. Kaufmann
  • Patent number: 10583193
    Abstract: Provided are compounds having the Formula I or II: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancers.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: March 10, 2020
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar F. Kaufmann
  • Patent number: 10584168
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: March 10, 2020
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann, Edwige Gros
  • Publication number: 20190358336
    Abstract: Provided herein are cell penetrating compounds having the Formula I: where, generally, each T is a thiol reactive group (e.g., a phosphorothioate), each L is a linker (e.g., a linear alkyl), and Y is a biologic (e.g., an antibody). Also provided are pharmaceutical compositions including the cell penetrating compounds, and methods of delivering the compound into a cell.
    Type: Application
    Filed: June 27, 2019
    Publication date: November 28, 2019
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar F. Kaufmann, Heehyoung Lee, Tong Zhu, Henry Hongjun Ji